Cargando…

Targeting the microRNA-34a as a Novel Therapeutic Strategy for Cardiovascular Diseases

Cardiovascular diseases (CVDs) are still the main cause of morbidity and mortality worldwide and include a group of disorders varying from vasculature, myocardium, arrhythmias and cardiac development. MicroRNAs (miRs) are endogenous non-coding RNAs with 18–23 nucleotides that regulate gene expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hua, Cun-Cun, Liu, Xin-Ming, Liang, Li-Rong, Wang, Le-Feng, Zhong, Jiu-Chang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828972/ https://www.ncbi.nlm.nih.gov/pubmed/35155600 http://dx.doi.org/10.3389/fcvm.2021.784044

Ejemplares similares

MicroRNA-Related Strategies to Improve Cardiac Function in Heart Failure
por: Zhou, Huatao, et al.
Publicado: (2021)

Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target
por: Leng, Qianru, et al.
Publicado: (2022)

microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation
por: de los Reyes-García, Ascensión M., et al.
Publicado: (2023)

Editorial: MicroRNAs in Heart Regeneration: Regulatory Mechanisms and Therapeutic Applications
por: Abdelwahid, Eltyeb, et al.
Publicado: (2022)

The microRNA Expression Profiling in Heart Failure: A Systematic Review and Meta-Analysis
por: Shen, Nan-Nan, et al.
Publicado: (2022)

MicroRNA Profiles in Normotensive and Hypertensive South African Individuals
por: Matshazi, Don M., et al.
Publicado: (2021)

Prognostic value of circulating microRNA-21-5p and microRNA-126 in patients with acute myocardial infarction and infarct-related artery total occlusion
por: Mi, Xiao-long, et al.
Publicado: (2022)

MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review
por: Chen, Liuying, et al.
Publicado: (2021)

Bioengineering Methods in MicroRNA-Mediated Direct Reprogramming of Fibroblasts Into Cardiomyocytes
por: Paoletti, Camilla, et al.
Publicado: (2021)

The crosstalk between STAT3 and microRNA in cardiac diseases and protection
por: Wu, Lan, et al.
Publicado: (2022)

microRNA-377 Signaling Modulates Anticancer Drug-Induced Cardiotoxicity in Mice
por: Henderson, John, et al.
Publicado: (2021)

Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis
por: Tang, Yuyan, et al.
Publicado: (2022)

microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases
por: de Lucia, Claudio, et al.
Publicado: (2017)

Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles
por: Diallo, Idrissa, et al.
Publicado: (2020)

Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA
por: Rogula, Sylwester, et al.
Publicado: (2022)

A meta-analysis of the diagnostic value of microRNA for hypertensive left ventricular hypertrophy
por: Fei, Su-Hai, et al.
Publicado: (2022)

Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy
por: Liu, Yamin, et al.
Publicado: (2019)

Deletion of MicroRNA-21 Impairs Neovascularization Following Limb Ischemia: From Bedside to Bench
por: Chang, Wei-Ting, et al.
Publicado: (2022)

MicroRNA-21 mediated cross-talk between cardiomyocytes and fibroblasts in patients with atrial fibrillation
por: Pradhan, Kabita, et al.
Publicado: (2023)

Editorial: Insights in cardiovascular therapeutics: 2021 – cell death, cardiovascular injuries, and novel targets of cardiovascular therapeutics
por: Xu, Keman, et al.
Publicado: (2022)

Identification of Novel Single-Nucleotide Variants With Potential of Mediating Malfunction of MicroRNA in Congenital Heart Disease
por: Liu, Wangkai, et al.
Publicado: (2021)

MicroRNAs: New Players in the Pathobiology of Preeclampsia
por: Bounds, Kelsey R., et al.
Publicado: (2017)

Mitochondrial Transfer in Cardiovascular Disease: From Mechanisms to Therapeutic Implications
por: Chen, Jun, et al.
Publicado: (2021)

MicroRNA-34a: A Novel Therapeutic Target in Fibrosis
por: Zhao, Min, et al.
Publicado: (2022)

Commentary: MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure
por: Schmitz, Boris, et al.
Publicado: (2018)

miRMap: Profiling 14q32 microRNA Expression and DNA Methylation Throughout the Human Vasculature
por: Goossens, Eveline A. C., et al.
Publicado: (2019)

Circulating MicroRNA-505 May Serve as a Prognostic Biomarker for Hypertension-Associated Endothelial Dysfunction and Inflammation
por: Yang, Qinbo, et al.
Publicado: (2022)

Editorial: Women in cardiovascular therapeutics
por: Yin, Liya, et al.
Publicado: (2023)

DPP3: From biomarker to therapeutic target of cardiovascular diseases
por: Ye, Peng, et al.
Publicado: (2022)

Roles of MicroRNAs in Glucose and Lipid Metabolism in the Heart
por: Du, Hengzhi, et al.
Publicado: (2021)

Role of MicroRNAs in the Pathogenesis of Coronary Artery Disease
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2021)

Editorial: MicroRNAs—clinical biomarkers for atrial fibrillation
por: Moscoso, Isabel, et al.
Publicado: (2023)

Editorial: Highlights for Cardiovascular Therapeutics in 2021 – Trained Immunity, Immunometabolism, Gender Differences of Cardiovascular Diseases, and Novel Targets of Cardiovascular Therapeutics
por: Yang, William Y., et al.
Publicado: (2022)

Expression profiling analysis reveals key microRNA–mRNA interactions in patients with transposition of the great arteries and systemic left and right ventricles
por: Abu-Halima, Masood, et al.
Publicado: (2023)

Editorial: Insights in cardiovascular therapeutics 2022—cardiovascular innate immunity
por: Xu, Keman, et al.
Publicado: (2023)

The role of lncRNA-mediated pyroptosis in cardiovascular diseases
por: Hu, Bo, et al.
Publicado: (2023)

Editorial: Micro- and macronutrient malnutrition in cardiovascular disease
por: Hobkirk, J. P., et al.
Publicado: (2023)

MicroRNA-1-Mediated Inhibition of Cardiac Fibroblast Proliferation Through Targeting Cyclin D2 and CDK6
por: Valkov, Nedyalka, et al.
Publicado: (2019)

Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction
por: Koval, Sergiy M., et al.
Publicado: (2020)

Circulating microRNA-125b Levels Are Associated With the Risk of Vascular Calcification in Healthy Community-Dwelling Older Adults
por: Chao, Chia-Ter, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bu9r292vefha7l3kg1m7aeldf0